Erythropoietin-derived peptide ARA290 mediates brain tissue protection through the beta-common receptor in mice with cerebral ischemic stroke
Summary
Showed that ARA-290 exerts neuroprotective effects comparable to erythropoietin in a mouse middle cerebral artery occlusion model, without causing erythropoiesis. The protective mechanism operates through the beta-common receptor, reducing neuronal apoptosis and inflammatory cytokines.
Key Findings
- ARA-290 provided neuroprotection comparable to EPO in cerebral ischemic stroke model
- Neuroprotective effect mediated specifically through the beta-common receptor
- Significantly reduced neuronal apoptosis and brain inflammation without erythropoiesis
Access Full Text
Read the complete published study from the original source.
View on Publisher SiteRelated Monographs
Related Studies
View all →Erythropoietin-derived nonerythropoietic peptide ameliorates experimental autoimmune neuritis by inflammation suppression and tissue protection
Liu Y, Luo B, Han F, et al.
PLoS ONE
Demonstrated that ARA-290, an EPO-derived nonerythropoietic peptide, significantly improved recovery in experimental autoimmune neuritis without inducing erythropoiesis. The peptide suppressed inflammation, promoted nerve regeneration and remyelination, and modulated T cell differentiation.
- ARA-290 improved nerve regeneration and remyelination without stimulating erythropoiesis
- Increased regulatory T cells and Th2 cells while decreasing Th1 cells
The erythropoietin-derived peptide ARA290 reverses mechanical allodynia in the neuritis model
Pulman KGT, Smith M, Mengozzi M, et al.
Neuroscience
Demonstrated that ARA-290 prevented the development of mechanical allodynia (neuropathic pain) in a nerve inflammation model. Both low and high doses were equally effective, suggesting potential for treating neuropathic pain where nerve injury is absent on clinical assessment.
- ARA-290 prevented development of mechanical allodynia in neuritis model
- Both 30 and 120 mcg/kg doses were equally effective